【摘要】 目的观察拉米夫定联合胸腺肽加乙肝疫苗治疗慢性乙型肝炎的临床效果。方法100例未曾接受过抗病毒治疗的慢性乙型肝炎患者随机分为治疗组和对照组,治疗组50例,给予拉米夫定100mg,每日一次口服,同时乙肝疫苗10μg皮下注射,每两周一次,胸腺肽20mg肌肉注射,隔日一次,共计26周,随后继续使用拉米夫定和乙肝疫苗26周,总疗程52周;对照组给予拉米夫定100mg·d-1,疗程52周。结果治疗结束时治疗组ALT下降、HBeAg/抗-HBe血清转换率明显高于对照组,差异有显著性(P<0·01),但HBVDNA下降差异无显著性(P<0·01),停药后随访6月、12月,治疗组ALT及HBVDNA下降、HBeAg/抗-HBe血清转换率明显高于对照组比,差异有显著性(P<0·01)。治疗组的完全应答率与对照组比,差异有高度显著性(P<0·01)。结论拉米夫定联合胸腺肽加乙肝疫苗能明显提高临床疗效及HBeAg/抗-HBe血清转换率及HBVDNA阴转率,且无明显毒性反应。更多还原

【Abstract】 Objective To observe the efficacy of lamivudine,thymopeptide and hepatitis B vaccine combination therapy for patients with chronic hepatitis B. Method One hundred of patients with chronic hepatitis B were randomly divided into combination treatment group(n=50)receiving lamivudine,thymopeptide and hepatitis B vaccine and lamivudine alone(n=50)therapy for 52 weeks.Results The alanine aminotransferase normalization,HBeAg/anti-Hbe seroconversion,HBV DNA negativity and the complete response rate in combination group at the end of treatment,6-month and 12-month follow-up were greater than in lamivudine alone group (P<0.01).Conclusion Lamivudine,thymopeptide and hepatitis B vaccine combination therapy has a better efficacy for patients with chronic hepatitis B.更多还原